GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PROLOR Biotech, Inc. (FRA:M3D) » Definitions » Credit Losses Provision

PROLOR Biotech, (FRA:M3D) Credit Losses Provision


View and export this data going back to . Start your Free Trial

What is PROLOR Biotech, Credit Losses Provision?

Credit Losses Provision only applies to banks.


PROLOR Biotech, Business Description

Traded in Other Exchanges
N/A
Address
Website
PROLOR Biotech, Inc., formerly known as Modigene Inc., was formed on August 22, 2003 under the laws of the state of Nevada under the name LDG, Inc. It was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. The Company develops proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company's products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development also comprise anti-obesity peptide oxyntomodulin, factor VIIa, interferon ß and erythropoietin, and atherosclerosis and rheumatoid arthritis long-acting therapies.